Tuesday, October 13, 2026

CBOE Went Down By Over 5% In The Last 24 Hours

ViaNews Editorial Team

October 10, 2023

CBOE Went Down By Over 5% In The Last 24 Hours

(VIANEWS) - CBOE (VIX) has been up by 5.14% for the last session's close. At 11:10 EST on Tuesday, 10 October, CBOE (VIX) is $16.79.

CBOE Range

Regarding CBOE's daily highs and lows, it's 4.38% down from its trailing 24 hours low of $17.56 and 14.34% down from its trailing 24 hours high of $19.60.

Regarding CBOE's yearly highs and lows, it's 8.11% up from its 52-week low and 52.1% down from its 52-week high.

Volatility

CBOE's last week, last month's, and last quarter's current intraday variation average was a negative 2.87%, a positive 1.28%, and a positive 4.35%, respectively.

CBOE's highest amplitude of average volatility was 3.59% (last week), 4.77% (last month), and 4.35% (last quarter), respectively.

News about

  • According to Zacks on Monday, 9 October, "The ETF tracking the performance of the S&P 500 VIX Short-Term Futures Index - ProShares VIX Short-Term Futures (VIXY Quick QuoteVIXY - Free Report) is also likely to gain in the short term on the Middle East crisis. "
  • According to DailyForex on Monday, 9 October, "The S&P 500 Confronts Heightened VolatilityThe 200-day EMA continues to capture considerable attention, shaping market sentiment.", "However, the S&P 500 remains oversold at this juncture, warranting caution among traders. "
  • According to MarketWatch on Monday, 9 October, "The U.S. Global Jets ETF shed 1.4% in premarket trading, while futures for the S&P 500 declined 0.5%. "

More news about CBOE (VIX).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,372 source documents archived
Query this data → isubstrate.com